Advanced

Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays.

Carlsson, Anders; Wuttge, Dirk LU ; Ingvarsson, Johan; Bengtsson, Anders LU ; Sturfelt, Gunnar LU ; Borrebaeck, Carl and Wingren, Christer (2011) In Molecular & Cellular Proteomics 10.
Abstract
Systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are two severe autoimmune connective tissue diseases. The fundamental knowledge about their aetiology is limited and the conditions display complex pathogenesis, multifaceted presentations, and unpredictable courses. Despite significant efforts, the lack of fully validated biomarkers enabling diagnosis, classification, and monitoring of disease activity represents significant unmet clinical needs. In this discovery study, we have for the first time used recombinant antibody microarrays for miniaturized, multiplexed serum protein profiling of SLE and SSc, targeting mainly immunoregulatory proteins. The data showed that several candidate SLE-associated multiplexed serum... (More)
Systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are two severe autoimmune connective tissue diseases. The fundamental knowledge about their aetiology is limited and the conditions display complex pathogenesis, multifaceted presentations, and unpredictable courses. Despite significant efforts, the lack of fully validated biomarkers enabling diagnosis, classification, and monitoring of disease activity represents significant unmet clinical needs. In this discovery study, we have for the first time used recombinant antibody microarrays for miniaturized, multiplexed serum protein profiling of SLE and SSc, targeting mainly immunoregulatory proteins. The data showed that several candidate SLE-associated multiplexed serum biomarker signatures were delineated, reflecting disease (diagnosis), disease severity (phenotypic subsets) and disease activity. Selected differentially expressed markers were validated using orthogonal assays and a second, independent patient cohort. Further, biomarker signatures differentiating SLE versus SSc were demonstrated, and the observed differences increased with severity of SLE. In contrast, the data showed that the serum profiles of SSc versus healthy controls were more similar. Hence, we have shown that affinity proteomics could be used to de-convolute crude, non-fractionated serum proteomes, extracting molecular portraits of SLE and SSc, further enhancing our fundamental understanding of these complex autoimmune conditions. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Molecular & Cellular Proteomics
volume
10
publisher
American Society for Biochemistry and Molecular Biology
external identifiers
  • wos:000290216700013
  • pmid:21350050
  • scopus:79955747971
ISSN
1535-9484
DOI
10.1074/mcp.M110.005033
project
CREATE Health
language
English
LU publication?
yes
id
90e8ba91-a2a6-41d3-87ef-1c9d3ab1bb79 (old id 1831360)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21350050?dopt=Abstract
date added to LUP
2011-03-01 18:06:06
date last changed
2017-10-01 05:00:16
@article{90e8ba91-a2a6-41d3-87ef-1c9d3ab1bb79,
  abstract     = {Systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are two severe autoimmune connective tissue diseases. The fundamental knowledge about their aetiology is limited and the conditions display complex pathogenesis, multifaceted presentations, and unpredictable courses. Despite significant efforts, the lack of fully validated biomarkers enabling diagnosis, classification, and monitoring of disease activity represents significant unmet clinical needs. In this discovery study, we have for the first time used recombinant antibody microarrays for miniaturized, multiplexed serum protein profiling of SLE and SSc, targeting mainly immunoregulatory proteins. The data showed that several candidate SLE-associated multiplexed serum biomarker signatures were delineated, reflecting disease (diagnosis), disease severity (phenotypic subsets) and disease activity. Selected differentially expressed markers were validated using orthogonal assays and a second, independent patient cohort. Further, biomarker signatures differentiating SLE versus SSc were demonstrated, and the observed differences increased with severity of SLE. In contrast, the data showed that the serum profiles of SSc versus healthy controls were more similar. Hence, we have shown that affinity proteomics could be used to de-convolute crude, non-fractionated serum proteomes, extracting molecular portraits of SLE and SSc, further enhancing our fundamental understanding of these complex autoimmune conditions.},
  author       = {Carlsson, Anders and Wuttge, Dirk and Ingvarsson, Johan and Bengtsson, Anders and Sturfelt, Gunnar and Borrebaeck, Carl and Wingren, Christer},
  issn         = {1535-9484},
  language     = {eng},
  publisher    = {American Society for Biochemistry and Molecular Biology},
  series       = {Molecular & Cellular Proteomics},
  title        = {Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays.},
  url          = {http://dx.doi.org/10.1074/mcp.M110.005033},
  volume       = {10},
  year         = {2011},
}